Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adam Morse

Sports Medicine Temple Terrace, FL Doctor of Osteopathy

NPI 1255338059 CMS profile 102264

13020 N Telecom Pkwy, Temple Terrace, FL 33637

Open in the dashboard

General payments

$4,972

132 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adam Morse of Temple Terrace, FL is reported in the CMS Open Payments database as having received $4,972 across 132 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 42nd percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $183 2
2024 General $1,412 22
2023 General $470 17
2022 General $273 9
2021 General $332 19
2020 General $543 24
2019 General $1,759 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Morse
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Adam Morse were reported at $183. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Adam Morse Sports Medicine median Middle half National median
2019 $1,759 $1,176 $199–$4,249 $163
2020 $543 $708 $96–$2,890 $114
2021 $332 $1,213 $152–$3,994 $132
2022 $273 $1,230 $159–$3,998 $149
2023 $470 $584 $146–$2,836 $160
2024 $1,412 $628 $163–$3,168 $164
2025 $183 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $1,013 31 payments
  2. Linvatec Corporation $980 4 payments
  3. Coastal Medical Technologies LLC $728 6 payments
  4. Horizon Therapeutics plc $623 54 payments
  5. Zimmer Biomet Holdings, Inc. $460 9 payments
  6. Ferring Pharmaceuticals Inc. $365 15 payments
  7. Dunamis Medical, LLC $255 1 payment
  8. Vericel Corporation $253 3 payments
  9. DePuy Synthes Sales Inc. $72 3 payments
  10. Djo, LLC $67 1 payment
  11. Other $155 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,172 131 payments
  2. Consulting Fee $800 1 payment
Products named General payments · program years 2019–2025
  1. DUEXIS $387 36 payments
  2. EUFLEXXA $365 15 payments
  3. Tricera Handpiece $205 4 payments
  4. PENNSAID $160 12 payments
  5. Coblation Wands $155 3 payments
  6. BIOBRACE 23MM $152 2 payments
  7. MICRORAPTOR Knotless Anchor $129 3 payments
  8. MACI Orthopedics $121 1 payment
  9. MACI Cellular Therapy $118 1 payment
  10. Biosure $109 1 payment
  11. Other $1,392 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

41

Median for Sports Medicine: 144

Drug cost

$221

Median for Sports Medicine: $1,027

Branded share of claims

0%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 16 $156
Meloxicam Generic 25 $65

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$28,845

Of which drugs: $6,280

Medicare patients

56

Average age 65

Services billed

1,950

35 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Ischemic heart disease 34%
Chronic kidney disease 27%
Diabetes 25%
Cancer 20%
Alzheimer's or dementia 0%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 27 504 $363

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record